FDA approves Dompé’s Oxervate for rare eye disease treatment
Dompé farmaceutici, an Italian pharmaceutical company, has achieved a milestone with the U.S. Food and Drug Administration (FDA) approval of Oxervate (cenegermin) eye drops for the treatment of neurotrophic keratitis, a rare degenerative eye disease. This approval marks Oxervate as the first FDA-sanctioned drug specifically for this condition. Details on Neurotrophic Keratitis: Neurotrophic keratitis is […]